Date: 2017-09-20
Type of information: Clinical research agreement
Compound: MABp1 (bermekimab)
Company: XBiotech (USA - TX) Cedars-Sinai Medical Center (USA - CA)
Therapeutic area: Cancer - Oncology
Type agreement: clinical research
Action mechanism:
- monoclonal antibody. MABp1 is a monoclonal antibody targeting interleukin-1 alpha (IL-1 alpha).
Disease: patients with advanced pancreatic adenocarcinoma and cachexia
Details:
- • On September 20, 2017, XBiotech announced its agreement with Cedars-Sinai Medical Center located in Los Angeles, California, whereby XBiotech will provide its interleukin-1 alpha antagonist, MABp1, for a Phase I single arm study evaluating the maximum tolerated dose of Onivyde? (Irinotecan liposome injection) and 5-fluorouracil/folinic acid in combination with MABp1 in a cohort of patients with advanced pancreatic adenocarcinoma and cachexia. The study will also assess efficacy using various secondary measures including changes in lean body mass, weight stability, IL-6 levels, overall and progression free survival as well as evaluation of the relationship between treatment tolerance and patient functional status.
- Andrew Hendifar, M.D., Medical Oncology lead for the Gastrointestinal Disease Research Group at Cedars-Sinai and Co-Director of Pancreas Oncology, will be leading the study which is planned to enroll a total of 16 patients at the Cedars-Sinai Medical Center. Onivyde will be given intravenously with MABp1 and 5-fluorouracil/folinic acid every two weeks until disease progression.
Financial terms:
Latest news:
Is general: Yes
